- BioNTech's CTLA-4 antibody gotistobart shows 8.5-month survival boost in previously treated lung cancer patientsBioNTech reported new data on its CTLA-4 targeting antibody gotistobart in lung cancer. The study focused on patients whose disease had progressed after prior therapy. Those receiving gotistobart…
- GSK reports 94% response rate for Jideytro in ROS1-positive lung cancer at World ConferenceGSK is moving a newly acquired lung-cancer drug, Jideytro, toward FDA review after presenting data at the World Conference on Lung Cancer. The conference data showed a 94% response rate when Jidey…